🧪🧪 In a clinical trial among adults with obesity, retatrutide resulted in significant weight reduction, reduced pain in participants with knee osteoarthritis, and reduced apnea–hypopnea events in participants with obstructive sleep apnea
www.nejm.org/doi/full/10....
nejm.org
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity | NEJM
Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. In this phase 3, randomized, double-blind trial, we assign...
